Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial

OBJECTIVE: To evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA). METHODS: This was a multi-centre, randomised, double-blind, parallel-group, placeb...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Tanaka, Yoshiya, Soen, Satoshi, Yamanaka, Hisashi, Yoneda, Toshiyuki, Tanaka, Sakae, Nitta, Takaya, Okubo, Naoki, Genant, Harry K, van der Heijde, Désirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585575/
https://www.ncbi.nlm.nih.gov/pubmed/31036625
http://dx.doi.org/10.1136/annrheumdis-2018-214827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585575/
https://www.ncbi.nlm.nih.gov/pubmed/31036625
http://dx.doi.org/10.1136/annrheumdis-2018-214827

Ejemplares similares